Biotech Executive Search for VC-Backed Companies

Building a biotech leadership team isn't an executive search problem with a scientific theme. It's a structural mismatch between how retained search traditionally works and how a pre-revenue, milestone-driven, investor-syndicated company actually operates. If you're running TA inside a VC-backed biotech, you're feeling it across every parallel mandate: the lead investor is pattern-matching every shortlist, the tranche clock keeps moving in, and most search firms still treat biotech CEO and C-suite hires like late-stage corporate roles with 6-month retained mandates and candidate pools built for boards that hire on track record. Pre-revenue biotech doesn't have six months. And track record isn't the same currency.

Inside a VC-backed biotech, the TA function rarely runs one search at a time. There's a CMO to fill before the IND, a CFO before the next tranche, and a CBO whenever the BD conversation gets serious, usually all in the same six-month window. This article covers what changes about hiring when the syndicate is a co-buyer, where the traditional retained model breaks down on biotech economics, and how to think about leadership transitions as planned milestones rather than emergencies.

Key Takeaways

• Biotech leadership hiring is dual-graded. Candidates have to clear both the operating company and the investor syndicate, and the TA leader running the search manages two clients with overlapping but distinct briefs.
• Founder-to-CEO transitions are the most common inflection point. When the science clears proof of concept, the leadership scorecard quietly changes.
• Three structural mismatches break retained search. Fees scaled to large-cap, timelines beyond runway, and specialist concentration that ignores Series A all compound in pre-revenue biotech.
• The investor pattern-matches more than the brief. Lead VCs lean heavily on prior portfolio experience, often more than the role specification itself, which means surfacing the investor brief in week one is non-negotiable for the TA leader.
• Below the C-suite is where TA leaders feel the volume. A biotech preparing for Series B and a regulatory filing in the same year typically fills 10 to 15 senior hires across clinical operations, regulatory, manufacturing, and commercial preparation in parallel.

Why Biotech Executive Hiring Doesn't Look Like Other Searches

Pre-revenue biotech runs on a financing structure no other industry matches at this scale. Capital arrives in tranches tied to milestones (IND-enabling studies, first-in-human dosing, Phase 2 readouts), and an executive's tenure is measured in inflection points, not fiscal years. That changes who the right hire is, and when. This page focuses on the practical implications for hiring; the underlying mechanics of how search firms operate are covered in the broader executive search guide.

The European context makes the problem sharper. The capital base is thinner, the syndicates are smaller, and the pool of executives who have actually scaled a European biotech from preclinical to a registered product is smaller still. The leaders with public-company experience are often US-listed and US-based, which reshapes both the search universe and the relocation conversation.

Hiring is no longer a back-office consequence of fundraising. It is the fundraise.

That structural reality flows directly into hiring. Recent industry research on biopharma venture financing found that biotech VC fundraising in 2024 was above pre-pandemic levels, with early venture rounds reaching US$15.5 billion, but capital is flowing in larger rounds to significantly fewer companies. Investors are seeking certainty in scientific evidence and seasoned management teams. The bar for the management team is now part of the bar for the round.

The Founder-to-CEO Question Every VC-Backed Biotech Faces

The hardest hiring decision in early biotech rarely shows up as a job spec. It shows up as a quiet conversation between the lead investor and the board about whether the scientific founder should still be running the company in twelve months. The signals are usually visible long before the decision is made. The question is whether the board is willing to act on them.

Bruce Booth at Atlas Venture, writing on twenty years of early-stage biotech VC, put it directly: by the time you know you need a leadership change, you're probably late. The signals are usually visible early:

• Lack of traction telling the external story to investors and partners
• Lack of accountability or detailed focus on execution
• Inability to recruit and retain a stellar team

By the time the board fully processes those signals, the tradeoffs in the boardroom usually delay the decision past the point where it would have been clean.

The founder isn't failing as a scientist. The role is changing faster than the founder is.

A practical self-diagnosis for the TA leader running searches inside the company:

• Investor meetings are getting harder, not easier, and the pushback is on commercial credibility, not the science.
• Senior hires are stalling at the offer stage, with candidates citing concerns about leadership rather than the asset.
• The CEO is still the technical authority in every cross-functional meeting, including ones where they shouldn't be.
• Cash discipline is being managed reactively, with each tranche feeling like a survival event rather than a planned milestone.
• The board agenda has drifted toward operating updates because strategic conversations don't have a counterpart at the table.

If three or more apply, the company is not facing a hiring decision. It is facing a leadership transition that the next financing will force one way or the other, and the TA leader who sees it first has the credibility to propose how the next search runs.

The Roles That Define Pre-Revenue Biotech Leadership

CEO is the headline hire, but the real leverage in a VC-backed biotech sits across four to five roles that have to be sequenced with the science.

• CSO: Owns scientific direction and the translational research agenda. Often the founder's natural counterpart, or the role the founder transitions into when a commercial CEO is brought in.
• CMO: Owns clinical strategy and regulatory pathway. Usually hired between IND-enabling work and first-in-human, when the asset moves from preclinical to active trial design.
• CFO: Owns capital structure, investor relations, and fundraising mechanics. Hired around the financing event that takes the company from seed-and-Series-A territory into the institutional capital markets.
• CBO or Head of BD: Owns partnership strategy, deal structuring, and corporate development. Hired when the asset is mature enough to attract serious pharma partnership conversations.

Each of these roles draws from a narrow pool. Eurostat data on human resources in science and technology shows that of the 73.8 million people employed in science and technology in the EU in 2024, more than 33.4 million were senior. The regions with the highest density of S&T occupations cluster around a handful of capital cities and university hubs, like Hamburg, Utrecht, and the Nordic capitals, and biotech executive talent is a thin slice of that already-concentrated map.

Most candidates with end-to-end pre-revenue experience have worked at three or four prior biotechs, often inside the same investor networks. The same names circulate, and the same search firms pitch them.

That concentration is part of why hiring takes so long: the pool isn't deep, and the candidates who matter are usually already in active conversations with two or three other companies. This dynamic is shared across the broader life sciences executive search landscape, but pre-revenue biotech amplifies it because the time pressure is sharper and the financing milestones are harder.

The cost of mis-sequencing is real. Hire a CMO too early and the company is paying for clinical leadership it can't yet fully use. Hire a CFO too late and the next round is being negotiated by someone learning the capital structure on the job. The order matters as much as the names.

What the C-suite headlines miss is the volume below them. A biotech preparing for a Series B and a regulatory filing in the same year typically fills 10 to 15 senior hires below the C-suite across clinical operations, regulatory, manufacturing, and commercial preparation, on a compressed timeline. The TA leader running those parallel searches doesn't have time to retain a new firm for each one, and the candidate market doesn't sit still long enough to make sequential searches work.

How Investor Dynamics Reshape the Search

In most industries, the board hires the executive. In VC-backed biotech, the lead investor effectively has informal veto over the top hires, and the rest of the syndicate has strong opinions. That changes what a search actually is. The candidate is being evaluated against the company's needs and against the lead investor's pattern-match from prior portfolio companies, often simultaneously.

This shows up most clearly at the CEO level. Korn Ferry's annual EMEA CEO succession review found that 6 out of 10 EMEA countries surveyed cited company performance as a significant catalyst for unplanned successions, and 8 out of 10 of those countries reported that 50% or more of new CEO appointments were internal promotions. In biotech, that internal-promotion default doesn't quite apply, because the bench is usually too thin. So when a transition is needed, the syndicate reaches into its network. That network is the search.

The practical implication is that a biotech executive search has two clients, not one. The brief from the company describes the role. The brief from the lead investor describes the candidate. They aren't always identical.

A search process that doesn't surface and reconcile both briefs early will produce shortlists that look strong on paper and stall in reference calls.

This is also why search timing matters as much as search quality: the closer a hire sits to a financing event, the more the investor brief dominates, and the less flexibility the company has to make a non-consensus pick.

Why Retained-Search Economics Don't Fit Biotech

Retained executive search was built around large-cap corporate clients with predictable cash, multi-year strategic plans, and 6 to 9 month timelines. Pre-revenue biotech has none of those. Cash arrives in tranches, the strategic plan is rewritten with each clinical readout, and the timeline is whatever the runway says it is.

Three structural mismatches show up repeatedly.

The fee mismatch

A retained search billed at one-third of first-year cash compensation lands hard on a company that just stretched its runway by laying off a quarter of staff. EY's 2025 Biotech Beyond Borders report found that 2024 follow-on financings dropped to just $19.9 billion, the worst rates since 2016 and roughly a third of boom-year levels, while public biotechs trimmed their workforce by 3.1% to conserve cash. The cash discipline of the buyer doesn't match the cost structure of the search.

The timeline mismatch

A traditional retained mandate runs 16 to 24 weeks from kickoff to signed offer. Many pre-revenue biotechs can no longer plan that far out. The BIA UK Biotech Financing Q1 2025 report found that UK biotech VC deal count fell to 15 in Q1 2025 (from 18 in Q1 2024), with two megadeals (Isomorphic Labs at £449M and Verdiva Bio at £327M) accounting for most of the £881M raised, a UK-specific picture but indicative of the wider European pattern. Tranches are being negotiated tighter, and milestones are being moved closer in.

A search that takes longer than the gap between financings is, structurally, a search that won't close.

The specialist-concentration mismatch

Biotech bench depth sits inside the same handful of search practices, and senior partners are usually allocated to the biggest mandates. A Series A biotech competing for partner attention against a Series C in the same portfolio is going to lose. This is why interim and fractional executive hiring has become a meaningful pattern in biotech, especially at the CMO and CFO levels. It gives boards a credible bench while a permanent search runs in parallel, without the runway risk of a vacant seat.

The pattern matters beyond biotech specifically. The startup-specific dynamics of hiring executives at venture-backed companies (equity structure, board expectations, founder transitions) compound everything in this section. The biotech overlay is that the science adds a hard, externally-measured clock that other startups don't have.

The Search Is the Strategy

Biotech executive search isn't a hiring exercise that happens around the science. The search is the strategy, because the syndicate evaluates the team as part of the asset.

The TA leaders who get this right treat leadership transitions as planned milestones, not emergencies. They keep a warm bench between financings, run multiple specialist searches in parallel when the company has to fill 10 to 15 senior roles inside a single financing window, and reconcile the company brief with the investor brief from week one. The ones who don't end up running a search against a runway clock that was set before the search began, and explaining to the board why the next financing arrived before the next leader did.

Frequently Asked Questions

How do I handle the 10 to 15 sub-C-suite hires my biotech needs during scale-up?

A biotech preparing for a Series B and a regulatory filing in the same year typically needs to fill 10 to 15 roles below the C-suite (clinical operations, regulatory, manufacturing, commercial preparation) on a compressed timeline. That is where on-demand recruiting replaces the patchwork of contingent agencies many biotechs default to during scale-up. You get sustained sourcing capacity across roles instead of one-off mandates, and the executive bench is being built in parallel without compounding retainer fees.

How do I run multiple C-suite searches in parallel without paying three retained fees?

Pre-revenue biotech often needs CMO, CFO, and CBO or Head of BD on overlapping timelines, sometimes inside the same 12-month financing window. Three sequential retained searches at one-third of first-year cash compensation each compounds into a fee envelope most pre-IPO biotechs cannot justify. A recruiter marketplace gives you parallel specialist sourcing across roles under one coordination structure, without three separate retainer commitments. The TA leader keeps a single relationship instead of managing three vendors with conflicting timelines.

How do I keep the executive bench warm between financings?

The hardest part of biotech TA isn't the active search. It is the dead zone between financings, when the bench needs to stay current without an open mandate. Maintaining warm relationships with senior candidates across roles you'll need at the next milestone is a recurring task, not a project. The companies that get this right treat the bench as a planned milestone, not a reactive scramble triggered when a tranche closes.

How long should a biotech CEO search take, realistically?

For a VC-backed biotech with an active syndicate, 12 to 16 weeks from a confirmed brief to a signed offer is the working benchmark when the search runs in parallel with investor reference calls. Searches that drift to 20+ weeks are usually a sign that the brief was never fully reconciled between the company and the lead investor, not that the candidate pool was thin. The TA leaders who finish on time treat the investor as a co-author of the spec from week one.

What is the difference between biotech executive search and a recruiter marketplace?

A traditional retained executive search firm runs a single, sequential mandate through one named partner, typically over 16 to 24 weeks, with fees structured against first-year compensation. A recruiter marketplace gives the TA leader on-demand access to a curated pool of specialized recruiters who can run searches in parallel, with transparent performance data and a per-role rather than retained fee structure. For biotech specifically, the marketplace model fits when boards want multiple specialist searches running simultaneously (CMO, CFO, CBO) without committing the same fee envelope to each, and when timing is tied to tranches rather than calendars.